Benign and malignant cutaneous nasal lesions

Abstract

The nose is a structure of both cosmetic and functional importance. Cutaneous lesions of the nose occasionally represent a diagnostic challenge and involve the expertise of several specialties from dermatology, otolaryngology—head and neck surgery, infectious disease, and pathology, among others. We present a review of salient features of malignant and benign cutaneous nasal lesions which are of importance to physicians treating these complicated pathologies.

Keywords

basal cell carcinoma / cutaneous lymphoma / cutaneous nasal lesion / histiocytosis / melanoma / squamous cell carcinoma

References

[1] NCCN . Available at the website of NCCN Cancer Centers. 2024.

[2] American Cancer Society . Key statistics for melanoma skin cancer. Available at the website of American Cancer Society. 2022.

[3] Košec A , Rašić I , Pegan A , Solter D , Ćurković M , Bedeković V . Sex- and site-related significance in cutaneous head and neck melanoma. Ear Nose Throat J. 2021; 100 (5): 343- 349.

[4] Sand M , Sand D , Thrandorf C , Paech V , Altmeyer P , Bechara FG . Cutaneous lesions of the nose. Head Face Med. 2010; 6 (1): 7.

[5] Rastrelli M , Tropea S , Rossi CR , Alaibac M . Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014; 28 (6): 1005- 1011.

[6] Flint PW , Haughey BH , Lund VJ , Robbins KT , Thomas JR , Lesperance MM , Cummings Otolaryngology: Head and Neck Surgery. 7th ed. Vol. 1. 2021,: Elsevier.

[7] Dzwierzynski WW . Melanoma risk factors and prevention. Clin Plast Surg. 2021; 48 (4): 543- 550.

[8] American Cancer Society . UV (Ultraviolet) radiation and cancer risk. Available at the website of American Cancer Society. 2022.

[9] Jahn V , Breuninger H , Garbe C , Maassen MM , Moehrle M . Melanoma of the nose: prognostic factors, three-dimensional histology, and surgical strategies. Laryngoscope. 2006; 116 (7): 1204- 1211.

[10] Wee E , Wolfe R , Mclean C , Kelly JW , Pan Y . The anatomic distribution of cutaneous melanoma: a detailed study of 5141 lesions. Australas J Dermatol. 2020; 61 (2): 125- 133.

[11] Christopoulos G , Sergentanis TN , Karantonis F , et al. Surgical treatment and recurrence of cutaneous nasal malignancies: a 26-year retrospective review of 1795 patients. Ann Plast Surg. 2016; 77 (2): e2- e8.

[12] Amin MB , Greene FL , Edge SB , et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017; 67 (2): 93- 99.

[13] Lo SN , Ma J , Scolyer RA , et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram. J Clin Oncol. 2020; 38 (24): 2719- 2727.

[14] Wang YK , Gao Y , Liu J , et al. A comparative study of melanocytic nevi classification with dermoscopy and high-frequency ultrasound. Skin Res Technol. 2021; 28 (2): 265- 273.

[15] Curti BD , Faries MB . Recent advances in the treatment of melanoma. N Engl J Med. 2021; 384 (23): 2229- 2240.

[16] Khayat D , Rixe O , Martin G , et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003; 97 (8): 1941- 1946.

[17] Sladden MJ , Balch C , Barzilai DA , et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009 (4): Cd004835

[18] Etzkorn JR , Alam M . What is Mohs surgery? JAMA Dermatol. 2020; 156 (6): 716.

[19] Theunissen CCW , Lee MH , Murad FG , Waldman AH . Systematic review of the role of Mohs micrographic surgery in the management of early-stage melanoma of the head and neck. Dermatol Surg. 2021; 47 (9): 1185- 1189.

[20] Buchbinder EI , Desai A . CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39 (1): 98- 106.

[21] Krummel MF , Allison JP . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182 (2): 459- 465.

[22] Callahan MK , Kluger H , Postow MA , et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018; 36 (4): 391- 398.

[23] Hamid O , Cowey CL , Offner M , Faries M , Carvajal RD . Efficacy, safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma. Cancers. 2019; 11 (11): 1642.

[24] Hodi FS , Corless CL , Giobbie-Hurder A , et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013; 31 (26): 3182- 3190.

[25] D'Angelo SP , Larkin J , Sosman JA , et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017; 35 (2): 226- 235.

[26] Dummer R , Hauschild A , Santinami M , et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020; 383 (12): 1139- 1148.

[27] Ferrucci PF , Pala L , Conforti F , Cocorocchio E . Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021; 13 (6): 1383.

[28] Dabestani PJ , Dawson AJ , Neumeister MW , Bradbury CM . Radiation therapy for local cutaneous melanoma. Clin Plast Surg. 2021; 48 (4): 643- 649.

[29] Stucker FJNC , Lian TS . Cutaneous Malignancy in Head & Neck Surgery. Lippincott Williams & Wilkins; 2001. O.r. edition.

[30] Que SKT , Zwald FO , Schmults CD . Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018; 78 (2): 237- 247.

[31] Waldman A , Schmults C . Cutaneous squamous cell carcinoma. Hematol Oncol Clin N Am. 2019; 33 (1): 1- 12.

[32] Derebaşınlıoǧlu H , Özkaya NK . Analysis of basal cell carcinoma and squamous cell carcinoma according to nasal subunit location. Facial Plast Surg. 2021; 37 (3): 407- 410.

[33] Stang A , Khil L , Kajüter H , et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents. J Eur Acad Dermatol Venereol. 2019; 33 (Suppl 8(Suppl 8)): 6- 10.

[34] Corchado-Cobos R , García-Sancha N , González-Sarmiento R , Pérez-Losada J , Cañueto J . Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020; 21 (8): 2956.

[35] Nehal KS , Bichakjian CK . Update on keratinocyte carcinomas. N Engl J Med. 2018; 379 (4): 363- 374.

[36] Arits AH , Mosterd K , Essers BA , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, noninferiority, randomised controlled trial. Lancet Oncol. 2013; 14 (7): 647- 654.

[37] Brash DE , Rudolph JA , Simon JA , et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991; 88 (22): 10124- 10128.

[38] Wang NJ , Sanborn Z , Arnett KL , et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011; 108 (43): 17761- 17766.

[39] Lefort K , Mandinova A , Ostano P , et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev. 2007; 21 (5): 562- 577.

[40] Ang KK , Berkey BA , Tu X , et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62 (24): 7350- 7356.

[41] Rowe DE , Carroll RJ , Day CL, Jr . Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992; 26 (6): 976- 990.

[42] Wells JW . Cutaneous squamous cell carcinoma. Available at the website of Medscape. 2022.

[43] Schulte KW , Lippold A , Auras C , et al. Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol. 2005; 53 (6): 993- 1001.

[44] In GK , Thomas JS , Silk AW . Cutaneous malignancies of the head and neck. Hematol Oncol Clin N Am. 2021; 35 (5): 991- 1008.

[45] cancer.gov. Available at the website of National Cancer Institute. 2022 02/13/2022.

[46] NCCN . Available at the website of NCCN Cancer Centers. 2023.

[47] Bolognia JL , JV Schaffer , L Cerroni , Dermatology. 4th ed. Vol. 2. 2018.

[48] Kim JYS , Kozlow JH , Mittal B , et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018; 78 (3): 560- 578.

[49] Dessinioti C , Pitoulias M , Stratigos AJ . Epidemiology of advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2022; 36 (1): 39- 50.

[50] Ross AS , Schmults CD . Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006; 32 (11): 1309- 1321.

[51] Gore SM , Shaw D , Martin RCW , et al. Prospective study of sentinel node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2016; 38 (Suppl 1): E884- E889.

[52] Gurudutt VV , Genden EM . Cutaneous squamous cell carcinoma of the head and neck. J Skin Cancer. 2011; 2011: 502723.

[53] Becker JC , Stang A , DeCaprio JA , et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017; 3 (1): 17077.

[54] Jacobs D , Huang H , Olino K , et al. Assessment of age, period, and birth cohort effects and trends in Merkel cell carcinoma incidence in the United States. JAMA Dermatol. 2021; 157 (1): 59- 65.

[55] Albores-Saavedra J , Batich K , Chable-Montero F , Sagy N , Schwartz AM , Henson DE . Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010; 37 (1): 20- 27.

[56] Kaae J , Hansen AV , Biggar RJ , et al. Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010; 102 (11): 793- 801.

[57] Walsh NM , Cerroni L . Merkel cell carcinoma: a review. J Cutan Pathol. 2021; 48 (3): 411- 421.

[58] Kervarrec T , Tallet A , Miquelestorena-Standley E , et al. Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas. Mod Pathol. 2019; 32 (4): 499- 510.

[59] Kervarrec T , Gaboriaud P , Berthon P , et al. Merkel cell carcinomas infiltrated with CD33(+) myeloid cells and CD8(+) T cells are associated with improved outcome. J Am Acad Dermatol. 2018; 78 (5): 973- 982.e8.

[60] Jenkins LN , Howle JR , Veness MJ . Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: the Westmead Hospital experience. ANZ J Surg. 2019; 89 (5): 520- 523.

[61] Straker RJ, 3rd , Carr MJ , Sinnamon AJ , et al. Predictors of false negative sentinel lymph node biopsy in clinically localized Merkel cell carcinoma. Ann Surg Oncol. 2021; 28 (12): 6995- 7003.

[62] Karunaratne YG , Gunaratne DA , Veness MJ . Systematic review of sentinel lymph node biopsy in Merkel cell carcinoma of the head and neck. Head Neck. 2018; 40 (12): 2704- 2713.

[63] Andruska N , Mahapatra L , Brenneman RJ , et al. Reduced wide local excision margins are associated with increased risk of relapse and death from Merkel cell carcinoma. Ann Surg Oncol. 2021; 28 (6): 3312- 3319.

[64] Kieny A , Cribier B , Meyer N , Velten M , Jégu J , Lipsker D . Epidemiology of Merkel cell carcinoma. A population-based study from 1985 to 2013, in northeastern of France. Int J Cancer. 2019; 144 (4): 741- 745.

[65] Jaouen F , Kervarrec T , Caille A , et al. Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: a retrospective study. J Am Acad Dermatol. 2021; 84 (4): 921- 929.

[66] Kline L , Coldiron B . Mohs micrographic surgery for the treatment of Merkel cell carcinoma. Dermatol Surg. 2016; 42 (8): 945- 951.

[67] Mojica P , Smith D , Ellenhorn JD . Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol. 2007; 25 (9): 1043- 1047.

[68] Frohm ML , Griffith KA , Harms KL , et al. Recurrence and survival in patients with Merkel cell carcinoma undergoing surgery without adjuvant radiation therapy to the primary site. JAMA Dermatol. 2016; 152 (9): 1001- 1007.

[69] Kok DL , Wang A , Xu W , et al. The changing paradigm of managing Merkel cell carcinoma in Australia: an expert commentary. Asia Pac J Clin Oncol. 2020; 16 (6): 312- 319.

[70] Iyer JG , Parvathaneni U , Gooley T , et al. Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. Cancer Med. 2015; 4 (8): 1161- 1170.

[71] Blackmon JT , Dhawan R , Viator TM , Terry NL , Conry RM . Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: a report of 2 cases. JAAD Case Rep. 2017; 3 (3): 185- 189.

[72] Nghiem P , Kaufman HL , Bharmal M , Mahnke L , Phatak H , Becker JC . Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017; 13 (14): 1263- 1279.

[73] Salavati A , Prasad V , Schneider CP , Herbst R , Baum RP . Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177) lutetium-labeled somatostatin analogs in combination with radio-sensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med. 2012; 26 (4): 365- 369.

[74] Sand M , Sand D , Brors D , Altmeyer P , Mann B , Bechara FG . Cutaneous lesions of the external ear. Head Face Med. 2008; 4 (1): 2.

[75] Karlin J , Engelhard S , Russell M , Kirzhner M . Anatomic features of head and neck keratinocyte cancer in Virginia. Dermatol Surg. 2020; 46 (12): 1486- 1491.

[76] Winder G , Kawar M , Shalom A . Anatomical distribution of basal cell carcinoma in Israel using relative tumor density scores. Int J Dermatol. 2021; 60 (11): 1373- 1375.

[77] NCCN. Basal cell skin cancer, Version 1.2016. Available at the website of JNCCN. 2022.

[78] CK Bichakjian , SZ Aasi , M Alam , JS Andersen , Clinical practice guidelines in oncology basal cell skin cancer. National Comprehensive Cancer Network. 2016

[79] Rashtak S , Dierkhising RA , Kremers WK , Peters SG , Cassivi SD , Otley CC . Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015; 72 (1): 92- 98.

[80] Wade TR , Ackerman AB . The many faces of basal-cell carcinoma. J Dermatol Surg Oncol. 1978; 4 (1): 23- 28.

[81] McCormack CJ , Kelly JW , Dorevitch AP . Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. Arch Dermatol. 1997; 133 (5): 593- 596.

[82] McNaughton SA , Marks GC , Green AC . Role of dietary factors in the development of basal cell cancer and squamous cell cancer of the skin. Cancer Epidemiol Biomarkers Prev. 2005; 14 (7): 1596- 1607.

[83] Teh MT , Blaydon D , Chaplin T , et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. 2005; 65 (19): 8597- 8603.

[84] Wolf DJ , Zitelli JA . Surgical margins for basal cell carcinoma. Arch Dermatol. 1987; 123 (3): 340- 344.

[85] Kimyai-Asadi A , Alam M , Goldberg LH , Peterson SR , Silapunt S , Jih MH . Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol. 2005; 53 (3): 464- 468.

[86] Kim ES , Yang CE , Chung YK . Does reduction of the oncologic safety margin for facial basal cell carcinoma result in higher recurrence rates? Arch Craniofac Surg. 2021; 22 (3): 135- 140.

[87] Spiller WF , Spiller RF . Treatment of basal cell epithelioma by curettage and electrodesiccation. J Am Acad Dermatol. 1984; 11 (5 Pt 1): 808- 814.

[88] Thissen MR , Neumann MH , Schouten LJ . A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999; 135 (10): 1177- 1183.

[89] Julian C , Bowers PW , Pritchard C . A comparative study of the effects of disposable and Volkmann spoon curettes in the treatment of basal cell carcinoma. Br J Dermatol. 2009; 161 (6): 1407- 1409.

[90] Rowe DE , Carroll RJ , Day CL, Jr . Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989; 15 (3): 315- 328.

[91] Rowe DE , Carroll RJ , Day CL Jr . Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989; 15 (4): 424- 431.

[92] Mendenhall WM , Ferlito A , Takes RP , et al. Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. Oral Oncol. 2012; 48 (10): 918- 922.

[93] Petit JY , Avril MF , Margulis A , et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000; 105 (7): 2544- 2551.

[94] Voss N , Kim-Sing C . Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin. 1998; 16 (2): 313- 320.

[95] Braathen LR , Szeimies RM , Basset-Seguin N , et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007; 56 (1): 125- 143.

[96] Quirk C , Gebauer K , De'Ambrosis B , Slade HB , Meng TC . Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010; 85 (6): 318- 324.

[97] Bath-Hextall F , Ozolins M , Armstrong SJ , et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014; 15 (1): 96- 105.

[98] Griffin LL , Lear JT . Photodynamic therapy and non-melanoma skin cancer. Cancers. 2016; 8 (10): 98.

[99] Basset-Seguin N , Ibbotson SH , Emtestam L , et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008; 18 (5): 547- 553.

[100] Marmur ES , Schmults CD , Goldberg DJ . A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg. 2004; 30 (2 Pt 2): 264- 271.

[101] Hall VL , Leppard BJ , McGill J , Kesseler M , White J , Goodwin P . Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986; 37 (1): 33- 34.

[102] Wang I , Bendsoe N , Klinteberg C , et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001; 144 (4): 832- 840.

[103] Available at the website of FDA. 2019.

[104] Histiocytosis syndromes in children. Writing group of the histiocyte society. Lancet. 1987; 1 (8526): 208- 209.

[105] Emile JF , Abla O , Fraitag S , et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016; 127 (22): 2672- 2681.

[106] Kansal R , Quintanilla-Martinez L , Datta V , Lopategui J , Garshfield G , Nathwani BN . Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2013; 52 (1): 99- 106.

[107] Cong CV , Ly TT , Duc NM . Multisystem Langerhans cell histiocytosis: literature review and case report. Radiol Case Rep. 2022; 17 (5): 1407- 1412.

[108] Allen CE , Li L , Peters TL , et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010; 184 (8): 4557- 4567.

[109] Minkov M . Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011; 13 (2): 75- 86.

[110] Guyot-Goubin A , Donadieu J , Barkaoui M , Bellec S , Thomas C , Clavel J . Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer. 2008; 51 (1): 71- 75.

[111] Goyal G , Shah MV , Hook CC , et al. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes. Br J Haematol. 2018; 182 (4): 579- 581.

[112] Vassallo R , Ryu JH , Colby TV , Hartman T , Limper AH . Pulmonary langerhans'-cell histiocytosis. N Engl J Med. 2000; 342 (26): 1969- 1978.

[113] Howarth DM , Gilchrist GS , Mullan BP , Wiseman GA , Edmonson JH , Schomberg PJ . Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999; 85 (10): 2278- 2290.

[114] Bui A-TN , Larocca C , Giobbie-Hurder A , Jacobsen ED , LeBoeuf NR . Cutaneous Langerhans cell histiocytosis in adults: a retrospective cohort study of adult patients presenting to a single academic cancer center between 2003 and 2017. J Am Acad Dermatol. 2021; 5575 (1): 1- 94.

[115] Moravvej H , Yousefi M , Barikbin B . An unusual case of adult disseminated cutaneous Langerhans cell histiocytosis. Dermatol Online J. 2006; 12 (6): 13.

[116] Krooks J , Minkov M , Weatherall AG . Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol. 2018; 78 (6): 1047- 1056.

[117] Haupt R , Minkov M , Astigarraga I , et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013; 60 (2): 175- 184.

[118] Ehrhardt MJ , Humphrey SR , Kelly ME , Chiu YE , Galbraith SS . The natural history of skin-limited Langerhans cell histiocytosis: a single-institution experience. J Pediatr Hematol Oncol. 2014; 36 (8): 613- 616.

[119] Ho WL , Chan KC . Juvenile xanthogranuloma of the nasal vestibule. Ear Nose Throat J. 2012; 91 (10): 418- 419.

[120] Xu J , Ou X , Qin G . [Juvenile xanthogranuloma of the nasal vestibule: one case report]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014; 28 (14): 1085- 1087.

[121] Park SO , Jeong EC , Park JU , Kim SW . Xanthogranuloma in adolescence. Arch Plast Surg. 2012; 39 (1): 82- 84.

[122] Dehner LP . Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003; 27 (5): 579- 593.

[123] Kaposi sarcoma statistic. Available at the website of American Cancer Society. 2021.

[124] Tam HK , Zhang Z , Jacobson LP , et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 2002; 98 (6): 916- 922.

[125] Wilkins K , Turner R , Dolev JC , LeBoit PE , Berger TG , Maurer TA . Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol. 2006;54(2):189-206. quiz 207-10.

[126] Oktafiani D , Megasari NLA , Fitriana E , Nasronudin , Lusida MI , Soetjipto . Human herpes virus 8 antibodies in HIV-positive patients in Surabaya, Indonesia. 2020; 12 (Suppl 1): 8746.

[127] Kaloterakis A , Papasteriades C , Filiotou A , Economidou J , Hadjiyannis S , Stratigos J . HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece. Tissue Antigens. 1995; 45 (2): 117- 119.

[128] Fatahzadeh M . Kaposi sarcoma: review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113 (1): 2- 16.

[129] Folpe AL , Veikkola T , Valtola R , Weiss SW . Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol. 2000; 13 (2): 180- 185.

[130] Jussila L , Valtola R , Partanen TA , et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 1998; 58 (8): 1599- 1604.

[131] Carroll PA , Brazeau E , Lagunoff M . Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology. 2004; 328 (1): 7- 18.

[132] Régnier-Rosencher E , Guillot B , Dupin N . Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol. 2013; 68 (2): 313- 331.

[133] Brambilla L , Bellinvia M , Tourlaki A , Scoppio B , Gaiani F , Boneschi V . Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol. 2010; 162 (4): 854- 859.

[134] Nobler MP , Leddy ME , Huh SH . The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J Clin Oncol. 1987; 5 (1): 107- 112.

[135] Cuellar LE , Meza K , Holguín AM , et al. Clinicopathological features and mortality in patients with Kaposi sarcoma and HIV: a retrospective analysis of a thirty-year study from a Peruvian oncologic center. JCO Glob Oncol. 2022; 8: e2100379.

[136] Antman K , Chang Y . Kaposi's sarcoma. N Engl J Med. 2000; 342 (14): 1027- 1038.

[137] Dezube BJ . Acquired immunodeficiency syndrome-related Kaposi's sarcoma: clinical features, staging, and treatment. Semin Oncol. 2000; 27 (4): 424- 430.

[138] Willemze R , Cerroni L , Kempf W , et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133 (16): 1703- 1714.

[139] Campo E , Swerdlow SH , Harris NL , Pileri S , Stein H , Jaffe ES . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117 (19): 5019- 5032.

[140] Willemze R , Jaffe ES , Burg G , et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105 (10): 3768- 3785.

[141] Bolognia JL , Schaffer JV , Cerroni L . Cutaneous T-cell lymphoma. In: Dermatology. 4th ed. Elsevier; 2018.

[142] Zendri E , Pilotti E , Perez M , et al. The HTLV tax-like sequences in cutaneous T-cell lymphoma patients. J Invest Dermatol. 2008; 128 (2): 489- 492.

[143] Ballanger F , Bressollette C , Volteau C , Planche L , Dreno B . Cytomegalovirus: its potential role in the development of cutaneous T-cell lymphoma. Exp Dermatol. 2009; 18 (6): 574- 576.

[144] Vidulich KA , Rady PL , He Q , Tyring SK , Duvic M . Detection of highrisk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. Int J Dermatol. 2009; 48 (6): 598- 602.

[145] Akinbami AA , Osikomaiya BI , John-Olabode SO , et al. Mycosis fungoides: case report and literature review. Clin Med Insights Case Rep. 2014; 7: 95- 98.

[146] van Doorn R , Scheffer E , Willemze R . Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002; 138 (2): 191- 198.

[147] Ishibashi M , Ohshima K , Chen KR . Folliculotropic mycosis fungoides with eosinophilia and CD30+ large-cell transformation: a case with a fatal outcome presenting with multifocal lesions and leonine facies. Clin Exp Dermatol. 2010; 35 (4): e133- e136.

[148] Brown RA , Fernandez-Pol S , Kim J . Primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol. 2017; 44 (6): 570- 577.

[149] Kempf W , Pfaltz K , Vermeer MH , et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011; 118 (15): 4024- 4035.

[150] Kempf W , Kazakov DV , Paredes BE , Laeng HR , Palmedo G , Kutzner H . Primary cutaneous anaplastic large cell lymphoma with angioinvasive features and cytotoxic phenotype: a rare lymphoma variant within the spectrum of CD30+ lymphoproliferative disorders. Dermatology. 2013; 227 (4): 346- 352.

[151] Vergier B , Beylot-Barry M , Pulford K , et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol. 1998; 22 (10): 1192- 1202.

[152] Duvic M , Reddy SA , Pinter-Brown L , et al. Aphase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lympho-proliferative disorders. Clin Cancer Res. 2009; 15 (19): 6217- 6224.

[153] Kaffenberger BH , Kartono Winardi F , Frederickson J , Porcu P , Wong HK . Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin. J Clin Aesthet Dermatol. 2013; 6 (8): 29- 31.

[154] Desai A , Telang GH , Olszewski AJ . Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin. Ann Hematol. 2013; 92 (4): 567- 568.

[155] Patsinakidis N , Kreuter A , Moritz R , Stücker M , Altmeyer P , Möllenhoff K . Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy. Acta Derm Venereol. 2015; 95 (2): 233- 234.

[156] Duvic M , Tetzlaff MT , Gangar P , Clos AL , Sui D , Talpur R . Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015; 33 (32): 3759- 3765.

[157] Beltzung F , Ortonne N , Pelletier L , et al. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorders: a clinical, pathologic, and molecular study of 60 cases presenting with a single lesion: a multicenter study of the French cutaneous lymphoma study group. Am J Surg Pathol. 2020; 44 (7): 862- 872.

[158] Andreou A , Thermos G , Sklavounou-Andrikopoulou A . Extranodal NK/T cell lymphoma, nasal type with palatal involvement: a rare case report and literature review. Head Neck Pathol. 2021; 15 (2): 621- 627.

[159] Al-Hakeem DA , Fedele S , Carlos R , Porter S . Extranodal NK/T-cell lymphoma, nasal type. Oral Oncol. 2007; 43 (1): 4- 14.

[160] Wu X , LI P , Zhao J , et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol. 2008; 20 (8): 619- 625.

[161] Choi JH , Kim YJ , Kim H , Nam SH , Choi YW . Distribution of Basal cell carcinoma and squamous cell carcinoma by facial esthetic unit. Arch Plast Surg. 2013; 40 (4): 387- 391.

[162] Kidwai SM , Parasher AK , Lin FY . An unusual presentation of NK/T-cell lymphoma, nasal-type in the United States. Am J Otolaryngol. 2015; 36 (1): 80- 83.

[163] Sánchez-Romero C , Bologna-Molina R , Paes de Almeida O , et al. Extranodal NK/T cell lymphoma, nasal type: an updated overview. Crit Rev Oncol Hematol. 2021; 159: 103237.

[164] Suzuki R , Takeuchi K , Ohshima K , Nakamura S . Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008; 26 (2): 66- 72.

[165] Hathuc VM , Hristov AC , Smith LB . Primary cutaneous acral CD8(+) T-cell lymphoma. Arch Pathol Lab Med. 2017; 141 (11): 1469- 1475.

[166] Tjahjono LA , Davis MDP , Witzig TE , Comfere NI . Primary cutaneous acral CD8+ T-cell lymphoma-A single center review of 3 cases and recent literature review. Am J Dermatopathol. 2019; 41 (9): 644- 648.

[167] Bolognia JL , Schaffer JV , Cerroni L . B-cell lymphomas of the skin. In: Dermatology. 4th ed. Elsevier; 2018.

[168] Wanczinsnki MI , Pinto CAL , Trevisan F , Cunha PR , Grohs LMH . Primary cutaneous follicle center lymphoma simulating basal-cell carcinoma on the nasal ala. An Bras Dermatol. 2015; 90 (3 Suppl 1): 111- 114.

[169] Goyal A , LeBlanc RE , Carter JB . Cutaneous B-cell lymphoma. Hematol Oncol Clin N Am. 2019; 33 (1): 149- 161.

[170] Swerdlow SH . Cutaneous marginal zone lymphomas. Semin Diagn Pathol. 2017; 34 (1): 76- 84.

[171] Rosmaninho A , Alves R , Lima M , Lobo I , Amorim I , Selores M . Red nose: primary cutaneous marginal zone B-cell lymphoma. Leuk Res. 2010; 34 (5): 682- 684.

[172] Lima M . Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol. 2015; 90 (5): 687- 706.

[173] Bostan E , Akdogan N , Saglam Ayhan A , Ersoy Evans S . Widespread primary cutaneous diffuse large B-cell lymphoma, leg type, with nasal involvement. Int Wound J. 2019; 16 (4): 1063- 1067.

[174] Osada SI , Fujiwara Y , Higashi N , et al. Primary cutaneous diffuse large B-cell lymphoma, leg type, localized in the right periorbital region. J Dermatol. 2019; 46 (4): e130- e131.

[175] Shrivastava T , Li L , Tanwar S , et al. Enigmatic rapidly enlarging nasal mass that is not cancer. Case Rep Dermatol Med. 2020; 2020: 8855572- 8855573.

[176] McKinnell JA , Pappas PG . Blastomycosis: new insights into diagnosis, prevention, and treatment. Clin Chest Med. 2009; 30 (2): 227- 239.

[177] McBride JA , Gauthier GM , Klein BS . Clinical manifestations and treatment of blastomycosis. Clin Chest Med. 2017; 38 (3): 435- 449.

[178] Lindgren AL , Welsh KM . Primary nasal cutaneous blastomycosis in an immunocompetent patient from a nonendemic area. JAAD Case Rep. 2020; 6 (11): 1188- 1190.

[179] Abdalla M , Sax PE , Mostaghimi A , Miller AL , Loscalzo J . CLINICAL PROBLEM-SOLVING. On the nose. N Engl J Med. 2015; 373 (10): 955- 961.

[180] Özer M , Özsurekçi Y , Cengiz AB , Özçelik U , Yalçın E , Gököz Ö . Primary nasal tuberculosis in a 10-year-old girl. Can J Infect Dis Med Microbiol. 2016; 2016: 9128548.

[181] Dixit R , Dave L . Primary nasal tuberculosis. Lung India. 2008; 25 (2): 102- 103.

[182] Lerra S , Nazir T , Qadri SM , Kirmani M . Primary nasal tuberculosis-a rare clinical entity. Ear Nose Throat J. 2011; 90 (7): E12- E14.

[183] Gupta Y , Sinha R . Primary mucocutaneous tuberculosis of nose: one decade study. Int J Head Neck Surg. 2015; 6 (2): 69- 72.

[184] Patel AB , Rosen T . Herpes vegetans as a sign of HIV infection. Dermatol Online J. 2008; 14 (4): 6.

[185] Burlando M , Molle MF , Antonelli CT , Cozzani E , Parodi A . Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis. JAAD Case Rep. 2020; 6 (5): 386- 387.

[186] Meunier L , Guillot B , Lavabre-Bertrand T , Barnéon G , Izarn P , Meynadier J . [Chronic herpes of the pyodermatitis vegetans type in chronic cutaneous lymphoid leukemia]. Ann Dermatol Venereol. 1986; 113 (12): 1199- 1204.

[187] Blieden LS , Chévez-Barrios P , Yen MT . Herpes simplex vegetans presenting as an eyelid mass. Ophthalmic Plast Reconstr Surg. 2011; 27 (3): e58- e59.

[188] Ronkainen SD , Rothenberger M . Herpes vegetans: an unusual and acyclovir-resistant form of HSV. J Gen Intern Med. 2018; 33 (3): 393.

[189] Parsons K , Cipriano SD , Rosen LB , et al. Severe facial herpes vegetans and viremia in NFKB2-deficient common variable immunodeficiency. Front Pediatr. 2019; 7: 61.

[190] Wanat KA , Gormley RH , Rosenbach M , Kovarik CL . Intralesional cidofovir for treating extensive genital verrucous herpes simplex virus infection. JAMA Dermatol. 2013; 149 (7): 881- 883.

[191] Arinze F , Shaver A , Raffanti S . Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV). Infection. 2017; 45 (5): 705- 707.

[192] Ahmed A , El-badawy Z , Mohamed I . Rhinoscleroma: a detailed histopathological diagnostic insight. Int J Clin Exp Pathol. 2015; 8 (7): 8438- 8445.

[193] Andraca R , Edson RS , Kern EB . Rhinoscleroma: a growing concern in the United States? Mayo Clinic experience. Mayo Clin Proc. 1993; 68 (12): 1151- 1157.

[194] Castanedo Cázares JP , Martinez Rosales KI . Rhinoscleroma. 2015; 372 (25): e33.

[195] de Pontual L , Ovetchkine P , Rodriguez D , et al. Rhinoscleroma: a French national retrospective study of epidemiological and clinical features. Clin Infect Dis. 2008; 47 (11): 1396- 1402.

[196] Gaafar HA , Gaafar AH , Nour YA . Rhinoscleroma: an updated experience through the last 10 years. Acta Otolaryngol. 2011; 131 (4): 440- 446.

[197] Gamea M , El Tatawi F , Elnaggar A , Elafandi H , Ebeid K . Topical ciprofloxacin as treatment for rhinoscleroma in a series of 23 patients. Clin Otolaryngol. 2021; 46 (4): 893- 896.

[198] Jean L , Bolognia MD JVSM . Dermatology. Vol 1. Elsevier; 2018;

[199] leishmaniasis. Available at the website of WHO. 2023.

[200] Leishmaniasis. Available at the website of Centers for Disease Control and Prevention. 2024.

[201] Alam E , Abbas O , Moukarbel R , Khalifeh I . Cutaneous leishmaniasis: an overlooked etiology of midfacial destructive lesions. PLoS Negl Trop Dis. 2016; 10 (2): e0004426.

[202] Malekpour M , Esfandbod M . Cutaneous leishmaniasis. N Engl J Med. 2010; 362 (6): e15.

[203] Momeni AZ , Aminjavaheri M . Clinical picture of cutaneous leishmaniasis in Isfahan, Iran. Int J Dermatol. 1994; 33 (4): 260- 265.

[204] Reithinger R , Dujardin JC , Louzir H , Pirmez C , Alexander B , Brooker S . Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7 (9): 581- 596.

[205] Wigley JE . Eosinophilic granuloma.? Sarcoid of Boeck. Proc R Soc Med. 1945; 38 (3): 125- 126.

[206] Jean Bolognia JS , Cerroni L . Dermatology. Vol 1. 4th. elsevier; 2017.

[207] Smoller BR , Bortz J . Immunophenotypic analysis suggests that granuloma faciale is a gamma-interferon-mediated process. J Cutan Pathol. 1993; 20 (5): 442- 446.

[208] Pedace FJ , Perry HO , faciale G . A clinical and histopathologic review. Arch Dermatol. 1966; 94 (4): 387- 395.

[209] Deen J , Moloney TP , Muir J . Extrafacial granuloma faciale: a case report and brief review. Case Rep Dermatol. 2017; 9 (2): 79- 85.

[210] Al Dhafiri M , Kaliyadan F . Granuloma faciale. In: StatPearls. Stat-Pearls Publishing LLC.; 2022. StatPearls Publishing Copyright © 2022.

[211] Long H , Zhang G , Wang L , Lu Q . Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol. 2016; 50 (2): 189- 213.

[212] Cesinaro AM , Lonardi S , Facchetti F . Granuloma faciale: a cutaneous lesion sharing features with IgG4-associated sclerosing diseases. Am J Surg Pathol. 2013; 37 (1): 66- 73.

[213] Lindhaus C , Elsner P . Granuloma faciale treatment: a systematic review. Acta Derm Venereol. 2018; 98 (1): 14- 18.

[214] Poenitz N , Dippel E , Klemke CD , Qadoumi M , Goerdt S . Jessner's lymphocytic infiltration of the skin: a CD8+ polyclonal reactive skin condition. Dermatology. 2003; 207 (3): 276- 284.

[215] Petersen MP , Vestergaard V , Bygum A . Jessner lymphocytic infiltration - rare in childhood. Dermatol Online J. 2017; 23 (10).

[216] Lipsker D , Mitschler A , Grosshans E , Cribier B . Could Jessner's lymphocytic infiltrate of the skin be a dermal variant of lupus erythematosus? An analysis of 210 cases. Dermatology. 2006; 213 (1): 15- 22.

[217] Higgins CR , Wakeel RA , Cerio R . Childhood Jessner's lymphocytic infiltrate of the skin. Br J Dermatol. 1994; 131 (1): 99- 101.

[218] Stam J . [Sarcoidosis or Besnier-Boeck-Schaumann disease]. Tijdschr Ziekenverpl. 1980; 33 (17): 804- 807.

[219] Marchell RM , Judson MA . Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2010; 31 (4): 442- 451.

[220] Yanardağ H , Pamuk ON , Karayel T . Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. 2003; 97 (8): 978- 982.

[221] Redissi A , Penmetsa GK , Litaiem N . Lupus pernio. In: StatPearls. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies; 2023. Disclosure: Gopi Penmetsa declares no relevant financial relationships with ineligible companies. Disclosure: Noureddine Litaiem declares no relevant financial relationships with ineligible companies.

[222] Stagaki E , Mountford WK , Lackland DT , Judson MA . The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009; 135 (2): 468- 476.

[223] Adler BL , Wang CJ , Bui TL , Schilperoort HM , Armstrong AW . Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2019; 48 (6): 1093- 1104.

RIGHTS & PERMISSIONS

The Author(s). Eye & ENT Research published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.